A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia
Deepti Gadi(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Oreofe O. Odejide(Dana-Farber Cancer Institute), Alec Griffith(Oregon Health & Science University), Timothy Z. Lehmberg(Dana-Farber Cancer Institute), James A. Lederer(Brigham and Women's Hospital), Philippe Armand(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Emily M. Thrash(Dana-Farber Cancer Institute), Alexander R. Vartanov(Harvard University), John‐Hanson Machado(Broad Institute), Vanessa Rai(Harvard University), Stephen P. Martindale(Harvard University), Zixu Wang(Dana-Farber Cancer Institute), Brandon Lee(Dana-Farber Cancer Institute), Stacey M. Fernandes(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 20
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890